CEO Letter: Financing Tailwinds, US Showcase for Canurta Naturals, and New R&D Progress

Address from the CEO – October 2024

Dear Shareholders and Valued Supporters,

As we enter the final quarter of 2024, I’m excited to share promising news for the biotech sector. The Federal Reserve’s recent interest rate cuts have revitalized capital markets, easing the pressure on financing and sparking new opportunities for companies like Canurta. Investors are regaining confidence, and liquidity is increasing, creating favorable conditions for early-stage biotech companies.

As investor Anthony Pompliano remarked:

“Here we go. Global liquidity is expanding again. Stocks, real estate, commodities, and bitcoin are ready for the ultimate tailwind.”

This expanding liquidity offers a unique tailwind for Canurta as we continue to drive growth.

This fall, we’re sharpening our go-to-market strategy for both therapeutic and nutraceutical products. A major milestone is finalizing contract manufacturing relationships to solidify our supply chain. Additionally, we’re in the protocol writing stage for the First in Human trial of our neuroprotective compound, CNR-401, which continues to show promise.

Our strategic outreach is also yielding positive results. We’ve soft-circled CAD $750,000 of our $5 million Pre-Seed funding target and have several meetings with venture philanthropists and longevity-focused funds on the horizon. We aim for a hard close by November’s end and welcome interested parties to join us during this exciting phase.

The broader biotechnology and neuroscience sectors are also gaining momentum, with increasing interest in neurodegenerative disease treatments. Canurta’s commitment to pioneering therapies like CNR-401 aligns with this trend, positioning us as key players in the fight against ALS.

I extend my deepest gratitude to our investors, partners, and supporters. Your belief in our vision is what drives us forward, and with economic winds now in our favor, I am confident we are on the brink of transformational growth.

Thank you for your continued support.

Sincerely,

Akeem Gardner

CEO & Founder, Canurta Therapeutics

Canurta Naturals USA Showcases at the Canadian Health Food Association Tradeshow

Canurta Naturals USA, our sister company, exhibited its Sprouted Hemp Seed Powder at the Canadian Health Food Association (CHFA) Tradeshow in Toronto on September 21-22. The CHFA is Canada’s largest trade association dedicated to natural health and organic products.

Attendees had the opportunity to learn more about Canurta Naturals’ Sprouted Hemp Seed Powder, a versatile ingredient perfect for use in baked goods, shakes, and more. This event was an important step in showcasing the innovative applications of hemp-derived products to the broader health and wellness market.

Learn More

Connecting with Early-Stage Investors at the RESI Conference

On September 25, Canurta's Founder and CEO, Akeem Gardner, represented the company at the Redefining Early Stage Investments (RESI) Conference in Boston. This event provided an ideal platform for Akeem to share Canurta's latest advancements and strategic direction, while connecting with early-stage investors and partners.

The RESI Conference is renowned for bridging the gap between startups and early-stage investors, facilitating meaningful discussions around fundraising and partnership opportunities. This event allowed us to engage with investors who are aligned with Canurta’s vision for growth and innovation in botanical therapeutics.

Canurta's September Milestones

Research and Development

The Research and Development team has produced a second methylated flavonoid compound generated by Canurta’s biosynthesis platform.

Bioinformatics

The Digital Transformation Team's gene expression analysis of an ALS zebrafish model testing CNR-401 identified significant changes in genes linked to neuronal function, inflammation, and cellular stress, consistent with ALS mechanisms. This provides a strong foundation for ongoing research, with potential biomarkers also identified for further validation in zebrafish and other models. Expert feedback emphasized the value of multi-omics data, leading to plans for collaborations and larger-scale studies to advance ALS research.